Report
Valens Research

MRVI - Embedded Expectations Analysis - 2022 02 07

Maravai LifeSciences (MRVI) currently trades below corporate averages relative to Uniform earnings, with a 10.7x Uniform P/E (Fwd. V/E').

At these levels, markets are pricing in expectations for Uniform ROA to fade to 66%, accompanied by 12% Uniform asset growth.

Meanwhile, analysts expect Uniform ROA to improve to 136% in 2022, accompanied by 78% Uniform asset growth.

If sustained in perpetuity, these levels would imply a stock price closer to $531, representing significant equity upside for the firm. That said, the firm is unlikely to sustain current pandemic-related growth boosts going forward.

Moreover, the firm's most recent earnings call suggests management may have concerns about the COVID vaccine and non-COVID application demand.
Underlying
Maravai LifeSciences Holdings

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch